Drug intelligence / Profile preview

ceftriaxone + doxycycline

Development stage: Unknown
Modality: Small Molecules
Administration: Intramuscular, Intravenous, Oral

Overview

A combination antibiotic therapy consisting of ceftriaxone (a third-generation cephalosporin) and doxycycline (a tetracycline antibiotic). This combination is used primarily for treating various bacterial infections, leveraging the complementary mechanisms of action of both drugs to provide broad-spectrum coverage against a wide range of pathogens. It has shown significant efficacy in treating community-acquired pneumonia (CAP), sexually transmitted infections (particularly gonorrhea), bacterial meningitis, and intra-abdominal infections.

Targets

PBP (Penicillin-binding protein family)Bacterial RibosomeMMP12 (Macrophage Metalloelastase)

Beyond the preview

Go deeper on ceftriaxone + doxycycline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ceftriaxone + doxycycline.

Explore the full profile